Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 4/20 | 0.49 |
| ▸ | MMP14 | P50281 | 3/20 | 0.49 |
| ▸ | MMP2 | P08253 | 3/20 | 0.49 |
| ▸ | MMP1 | P03956 | 2/20 | 0.49 |
| ▸ | MMP3 | P08254 | 2/20 | 0.49 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | MMP7 | P09237 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5744082 | 0.89 | MME (0.57) | MMEFOLH1MMP9MMP14MMP2 | |
| SCHEMBL5743853 | 0.86 | MME (0.54) | MME | |
| SCHEMBL4811671 | 0.85 | MME (0.48) | MME | |
| SCHEMBL5744035 | 0.84 | MME (0.46) | MME | |
| SCHEMBL5743743 | 0.84 | MME (0.46) | MME | |
| SCHEMBL5743902 | 0.84 | NAALAD2 (0.46) | MMELTA4H | |
| SCHEMBL5743710 | 0.83 | MME (0.54) | MMELTA4HANPEP | |
| SCHEMBL5741688 | 0.81 | ALDH1A1 (0.47) | MMEMMP8 | |
| SCHEMBL5743693 | 0.81 | MME (0.51) | MMEMMP9LTA4HANPEPMMP8 | |
| SCHEMBL5742216 | 0.81 | MME (0.56) | MMEMMP9MMP14MMP2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1427423-B9 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2017-12-20 | — | — | EP | claimed |
| EP-1427423-B1 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2006-12-27 | — | — | EP | claimed |
| US-7132416-B2 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | claimed |
| US-20050038009-A1 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia | ALBIREO AB (SE) | 2005-02-17 | — | — | US | claimed |
| US-7132416-B2 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-20050038009-A1 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia | ALBIREO AB (SE) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038009-A1 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia | SLC10A2, SLC10A1, ABCB11 | MME 1556/4885FOLH1 2382/4885MMP9 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.